MODE OF ACTION OF H-LINKED IMMUNE RESPONSE-I R GENES

该项目的长期目标是通过以下方式确定机制： 哪些H-2连锁免疫应答（Ir）基因调节对T细胞的免疫应答， 细胞依赖性抗原 尽管Ia抗原是 Ir基因产物被广泛接受，但它不能解释Ia 抗原介导高度特异性的Ir基因功能。 我们以前的 研究支持这样的假设，即Ir基因控制是 刺激各种调节辅助和抑制T细胞亚群。 因此，本提案的具体目标侧重于详细的 在调节性T细胞亚群中的差异的表征 应答小鼠和无应答小鼠。 近交系小鼠对抗人IgG抗体应答的发展 合成多肽：L-谷氨酸60-L-丙氨酸30-L-酪氨酸10（GAT） 和L-谷氨酸50-L-酪氨酸（GT）以及一组蛋白质， 从不同物种获得的几种胰岛素变体用作模型 系统. 特异性辅助性T细胞克隆和抑制性T细胞克隆的开发 细胞杂交瘤作为同质调节性T细胞的来源， 持续期间内的 抑制性T细胞抑制反应的机制 将使用可溶性抗原特异性抑制因子进行分析， 抑制-诱导因子 精确了解Ir基因功能的临床重要性是 有证据表明，Ir基因也调节免疫反应， 人类 几种器官特异性自身免疫性疾病与 HLA复合体D/DR区的某些单倍型表明， 该基因座类似于鼠I区。 因此，Ir基因的作用 在小鼠实验性自身免疫性疾病的发展中， 作为模型系统进行研究。 一旦抑制性T细胞的生物学被很好地理解， 可能产生抑制因子来调节非预期免疫 具体回答。 因为设计一个新的 每一种疾病和每一个人的因素，我们将确定是否 特异性因子可以通过免疫调节剂靶向新抗原决定簇， 抗原桥 如果用一个信号就能抑制大量的反应， 因子，抑制因子的治疗潜力将是非常 很有希望 最终，这些研究可能会为预防 在胰岛素依赖性糖尿病患者中诱导抗胰岛素抗体， 逆转自身免疫性疾病的特异性抑制T细胞因子。

The long term objectives of this project are to determine the mechanisms by which H-2-linked immune response (Ir) genes regulate immune responses to T cell dependent antigens. Although the hypothesis that the Ia antigens are the Ir gene products is widely accepted, it does not explain how Ia antigens mediate the highly specific Ir gene functions. Our previous studies support the postulate that Ir gene control is the net result of the stimulation of various regulatory helper and suppressor T cell subsets. Thus, the specific aims of this proposal focus on the detailed characterization of differences in regulatory T cell subsets between responder and nonresponder mice. Development of antibody responses by inbred strains of mice to the synthetic polypeptides: L-glutamic acid60-L-alanine30-L-tyrosine10 (GAT) and L-glutamic acid50-L-tyrosine (GT) and a panel of proteins comprised of several insulin variants obtained from different species serve as model systems. Development of specific helper T cell clones and suppressor T cell hybridomas as sources of homogeneous regulatory T cells will be continued. The mechanisms by which suppressor T cells inhibit responses will be analyzed using soluble, antigen-specific suppressor factors and suppressor-inducer factors. The clinical importance of understanding precisely how Ir genes function is supported by evidence that Ir genes also regulate immune responses in humans. Several organ-specific autoimmune diseases are associated with certain haplotypes of the D/DR region of the HLA-complex suggesting that this locus is analogous to the murine I region. Thus, the role of Ir genes in development of experimental autoimmune diseases in mice will be investigated as a model system. Once the biology of suppressor T cells is well understood, it should be possible to produce suppressor factors to modulate indesirable immune responses specifically. Because it would not be feasible to design a new factor for every disease and every individual, we will determine whether specific factors can be targeted to neoantigenic determinants via an antigen bridge. If numerous responses can be suppressed with a single factor, the therapeutic potential of suppressor factors would be very promising. Ultimately these studies might provide the basis to prevent induction of anti-insulin antibodies in insulin-dependent diabetics and to reverse autoimmune diseases with specific suppressor T cell factors.